PeptideJournal
Guides17 min read

Peptides for Chronic Pain Management

Roughly one in five American adults lives with chronic pain. That number has climbed 25% since 1998, and the consequences ripple far beyond the individual -- lost wages, disability, depression, and a decades-long opioid crisis that killed over 80,000 people in 2021 alone [1].

Roughly one in five American adults lives with chronic pain. That number has climbed 25% since 1998, and the consequences ripple far beyond the individual -- lost wages, disability, depression, and a decades-long opioid crisis that killed over 80,000 people in 2021 alone [1]. The standard toolkit (NSAIDs, acetaminophen, opioids, nerve blocks, antidepressants) works for many people, but it leaves enormous gaps. NSAIDs erode the gut lining. Opioids create dependence. Neither class addresses the underlying tissue damage or neurological sensitization that keeps chronic pain cycling.

Peptides occupy a different space. Rather than masking pain signals, many of these molecules target the biological machinery behind persistent pain -- inflammatory cascades, damaged nerves, degraded cartilage, and sensitized receptors. Some are derived from proteins your body already makes. Others are synthetic compounds designed to hit specific molecular targets with minimal off-target effects.

This guide breaks down the peptides with the strongest research support for chronic pain, what scientists know about their mechanisms, and where the evidence stands right now.

Table of Contents

Why Chronic Pain Is So Hard to Treat

Chronic pain -- defined as pain lasting more than three months -- is not just acute pain that never went away. It involves structural changes in the nervous system itself. Peripheral nerves become hypersensitive (peripheral sensitization). Spinal cord neurons amplify normal signals into pain (central sensitization). Brain regions responsible for emotional processing get recruited into the pain experience, which is why chronic pain so often travels with anxiety and depression.

These changes mean that treating the original injury is not always enough. A herniated disc can heal, but the pain may persist because the nervous system has rewired itself to keep firing. The inflammatory markers TNF-alpha, IL-1-beta, and IL-6 stay elevated. Oxidative stress damages mitochondria in nerve cells. Cartilage and connective tissue degrade without adequate repair signals.

This is where peptides become relevant. Many of these molecules do not just block pain signals -- they address the tissue damage, inflammation, and neurological changes that keep chronic pain running.

How Peptides Approach Pain Differently

Conventional painkillers operate at a few well-understood chokepoints. NSAIDs block cyclooxygenase (COX) enzymes to reduce prostaglandin production. Opioids bind mu receptors to dampen pain perception. Gabapentinoids calm overexcited nerve cells.

Peptides work through a wider set of mechanisms:

  • Tissue repair: Peptides like BPC-157 and TB-500 accelerate healing in tendons, ligaments, muscles, and nerves -- addressing the source of pain rather than the symptom
  • Targeted anti-inflammatory action: Instead of broad immune suppression, peptides like KPV and GHK-Cu modulate specific pathways (NF-kB, TNF-alpha) without shutting down protective immune function
  • Receptor modulation: GLP-1-derived peptides directly inhibit TRPV1, a key pain receptor, through a mechanism entirely separate from opioid pathways
  • Neuronal repair: Several peptides promote nerve regeneration, BDNF production, and restoration of normal nerve signaling
  • Growth factor stimulation: Growth hormone secretagogues boost IGF-1, supporting tissue repair and reducing recovery time

The trade-off is maturity. Most peptide pain research is preclinical or in early clinical stages. But the science is moving fast, and several compounds already have human data supporting their use.

The Top Peptides for Chronic Pain Research

BPC-157: Tissue Repair From the Inside Out

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide originally isolated from human gastric juice. It is the most studied peptide for musculoskeletal healing and has direct relevance to chronic pain because much of its pain-reducing effect comes from repairing damaged tissue rather than blocking pain signals.

What the research shows:

A 2025 systematic review in the American Journal of Sports Medicine analyzed 36 studies spanning 1993 to 2024. Thirty-five were preclinical, and one was clinical. Across these studies, BPC-157 consistently improved healing outcomes in muscle, tendon, ligament, and bone injury models, with reduced inflammation as a common finding [2].

The one human study tracked 12 patients with chronic knee pain who received a single intra-articular BPC-157 injection. Seven of 12 reported relief lasting more than six months [3]. A separate retrospective study of 16 patients found that 11 of 12 who received BPC-157 alone had significant improvement in knee pain [4].

In a rat incisional pain model, BPC-157 showed direct anti-nociceptive (pain-reducing) effects, measured by reduced pain behaviors at the surgical site. The researchers attributed this to the peptide's combined anti-inflammatory and wound-healing properties [5].

In adjuvant arthritis models, rats treated daily with BPC-157 showed markedly reduced joint damage, with benefits appearing within two weeks and persisting through one year of treatment [6].

How it works:

BPC-157 activates the VEGFR2 receptor and the Akt-eNOS signaling axis, promoting new blood vessel formation and tissue repair. It suppresses TNF-alpha, IL-1-beta, and IL-6 while modulating the nitric oxide system -- upregulating the protective NOS-3 (eNOS) and NOS-1 (nNOS) isoforms while suppressing the inflammatory NOS-2 (iNOS) [2]. This shifts the balance from tissue destruction toward repair.

Evidence level: Strong preclinical data. Very limited human evidence from small pilot studies. No randomized controlled trials completed.

GLP-1 Peptides (Semaglutide and Relatives): The Pain-Receptor Connection

The discovery that GLP-1 peptides have direct analgesic properties was one of the more surprising findings in recent pain research. Semaglutide was developed for type 2 diabetes and obesity, but a growing body of evidence shows GLP-1 receptor agonists reduce pain through mechanisms entirely independent of weight loss.

What the research shows:

A landmark 2024 study in Experimental & Molecular Medicine showed that GLP-1 and its derivatives directly inhibit TRPV1, a receptor that sits on sensory neurons and plays a central role in pain signaling [7]. The researchers tested liraglutide, exendin-4, and exendin 9-39 on cultured sensory neurons and found all three blocked capsaicin-induced pain responses.

One fragment in particular -- exendin 20-29 -- relieved both acute pain (capsaicin-induced) and chronic pain (inflammatory and neuropathic models) in mice without causing hyperthermia, a dangerous side effect that has torpedoed previous TRPV1 antagonist drugs [7].

In clinical settings, the STEP-9 trial studied semaglutide in 407 patients with obesity and knee osteoarthritis. Patients experienced meaningful improvements in both pain scores and physical function alongside 13.7% weight loss [8]. While some of the pain reduction likely came from reduced mechanical load on the joints, the preclinical evidence suggests a direct analgesic component.

A 2025 review in The Journal of Headache and Pain catalogued GLP-1 receptor agonists' pain-reducing mechanisms: anti-inflammatory effects, beta-endorphin release, oxidative stress reduction, and neuroprotection [9]. The authors suggested these drugs could be repurposed for chronic pain conditions beyond their current metabolic indications.

How it works:

GLP-1-derived peptides bind to the extracellular portion of TRPV1 as noncompetitive inhibitors, blocking pain signaling without affecting the proton-sensing function of the receptor [7]. Separately, they reduce neuroinflammation in the spinal cord and promote neuronal survival through PI3K/Akt and MAPK pathways. Semaglutide specifically has been shown to inhibit neuroinflammation in diabetic neuropathic pain models [10].

Evidence level: Strong preclinical evidence for TRPV1 inhibition. Clinical trial data (STEP-9) for osteoarthritis pain. No dedicated chronic pain trials yet for GLP-1 agonists.

GHK-Cu: The Copper Peptide With Anti-Inflammatory Reach

GHK-Cu is a naturally occurring tripeptide found in human plasma, saliva, and urine. Plasma levels drop from around 200 ng/mL at age 20 to 80 ng/mL by age 60, a decline that correlates with slower healing and increased inflammation [11].

What the research shows:

Gene expression studies using the Broad Institute's Connectivity Map found that GHK modulates the expression of over 4,000 human genes -- roughly 6% of the genome. Many of these genes are directly involved in inflammation, pain signaling, and tissue repair [11].

GHK-Cu reduced TNF-alpha-induced secretion of the pro-inflammatory cytokine IL-6 in human dermal fibroblasts, leading researchers to propose it as an alternative to corticosteroids for inflammatory conditions [12]. In ischemic wound models, GHK-Cu accelerated healing while decreasing matrix metalloproteinases 2 and 9 and reducing TNF-beta levels [13].

Animal studies found GHK and its analogs reduced pain sensitivity in mice and modulated aggressive-defensive behavior in pain models in rats [14].

How it works:

GHK-Cu suppresses NF-kB-driven inflammation and reduces oxidative stress through multiple mechanisms. It stimulates production of VEGF (vascular endothelial growth factor), BDNF (brain-derived neurotrophic factor), and BMP-2 (bone morphogenetic protein 2). The copper ion plays a role in activating superoxide dismutase and other antioxidant enzymes. These combined effects target both the inflammatory and regenerative sides of chronic pain [11].

Evidence level: Extensive gene expression and in vitro data. Animal studies showing pain reduction. No dedicated human clinical trials for pain.

KPV: The Short Anti-Inflammatory Peptide

KPV is a tripeptide (lysine-proline-valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite being only three amino acids long, it retains much of the parent hormone's anti-inflammatory potency.

What the research shows:

KPV's primary mechanism involves direct inhibition of NF-kB, the master switch for inflammatory gene expression. By entering immune cells and blocking NF-kB nuclear translocation, KPV shuts down the production of TNF-alpha, IL-1-beta, and other pro-inflammatory mediators at the transcriptional level [15].

In colitis models, KPV reduced intestinal inflammation and tissue damage, suggesting relevance for inflammatory bowel disease-related pain [15]. Its mechanism is particularly relevant for conditions where chronic NF-kB activation drives persistent pain, including inflammatory arthritis, fibromyalgia, and neuropathic pain syndromes.

How it works:

KPV is small enough to enter cells directly. Once inside, it inhibits IKK-beta phosphorylation, preventing the degradation of IkB-alpha and keeping NF-kB sequestered in the cytoplasm. Without NF-kB reaching the nucleus, entire cascades of pro-inflammatory gene expression are suppressed [15].

Evidence level: Strong preclinical data for anti-inflammatory mechanisms. No dedicated human pain trials.

CJC-1295 and Ipamorelin: Growth Hormone Secretagogues for Recovery

CJC-1295 and Ipamorelin are growth hormone secretagogues -- compounds that stimulate your pituitary gland to release more growth hormone (GH). They are relevant to chronic pain because GH and its downstream mediator IGF-1 are central to tissue repair, and GH deficiency is common in people with chronic pain conditions.

What the research shows:

Subcutaneous CJC-1295 produced dose-dependent increases in GH levels (2- to 10-fold above baseline for six or more days) and IGF-1 levels (1.5- to 3-fold for 9-11 days) in healthy adults [16]. When combined, CJC-1295 and Ipamorelin work synergistically -- CJC-1295 extends the duration of GH release while Ipamorelin triggers strong, clean GH pulses without raising cortisol or prolactin [17].

A 2020 pilot study found that increased GH circulation preserved quadriceps strength in patients recovering from ACL reconstruction [18]. GH and IGF-1 are well-established drivers of protein synthesis, collagen production, and cellular regeneration -- all processes impaired in chronic pain conditions involving tissue degradation.

CJC-1295 also improves sleep quality by increasing REM sleep duration, which matters because poor sleep is both a consequence and amplifier of chronic pain [17].

How it works:

CJC-1295 mimics GHRH (growth hormone-releasing hormone), binding to pituitary receptors to trigger GH release. Its DAC (Drug Affinity Complex) modification extends its half-life to 6-8 days. Ipamorelin is a selective ghrelin mimetic that stimulates GH pulses through GHS-R1a receptors. Together, they restore more youthful GH output, supporting tissue repair, reducing inflammation, and improving recovery capacity [16, 17].

Evidence level: Well-established pharmacokinetics in human studies. GH/IGF-1 elevation consistently demonstrated. Limited direct evidence for chronic pain specifically, though GH's role in tissue repair is well-documented.

TB-500: Systemic Tissue Repair

TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid protein involved in cell migration, blood vessel formation, and inflammation regulation. While BPC-157 tends to work locally at injury sites, TB-500 has more systemic tissue-repair properties.

What the research shows:

Thymosin beta-4 promoted healing in multiple preclinical models -- dermal wounds, corneal injuries, cardiac damage, and neuronal injuries. In cardiac ischemia-reperfusion models, it reduced infarct size and preserved ventricular function [19]. The peptide stimulates both angiogenesis (new blood vessel growth) and cell migration, making it relevant for chronic pain conditions rooted in poor tissue perfusion or incomplete healing.

In a small retrospective study, the combination of BPC-157 and TB-500 (thymosin beta-4) injected intra-articularly improved knee pain in 4 of 4 patients who received both compounds [4].

How it works:

TB-500 sequesters G-actin monomers, regulating actin polymerization and enabling cell migration to injury sites. It has anti-inflammatory, anti-apoptotic, and pro-angiogenic properties. Clinically, these translate to faster tissue repair, reduced scar formation, and improved blood flow to damaged areas [19].

Evidence level: Solid preclinical evidence across tissue types. Advanced clinical trials in cardiac and ophthalmologic applications. Very limited pain-specific human data.

SS-31: Mitochondrial Protection Against Pain Signaling

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane. Its relevance to chronic pain lies in the growing recognition that mitochondrial dysfunction drives both inflammatory pain and neuropathic pain.

What the research shows:

In a lipopolysaccharide-induced neuroinflammation model, SS-31 improved mitochondrial function, reduced synaptic impairment, and restored memory in mice [20]. Its capacity to reduce oxidative stress at the mitochondrial level is relevant because reactive oxygen species (ROS) from damaged mitochondria activate pain-signaling pathways including NLRP3 inflammasome assembly and NF-kB nuclear translocation.

SS-31 has completed multiple clinical trials for mitochondrial myopathy (Barth syndrome) and heart failure, demonstrating that it reaches target tissues and improves mitochondrial function in humans [21].

How it works:

SS-31 binds to cardiolipin in the inner mitochondrial membrane, stabilizing the electron transport chain and reducing electron leak. This lowers ROS production at its source rather than scavenging free radicals after they form. By protecting mitochondrial function in nerve cells, SS-31 may help break the cycle of oxidative stress, inflammation, and pain sensitization [20, 21].

Evidence level: Strong preclinical data for mitochondrial protection and anti-inflammatory effects. Human trials for mitochondrial diseases. No dedicated chronic pain trials.

Peptide Comparison Table

PeptidePrimary Pain MechanismEvidence LevelAdministrationKey Advantage
BPC-157Tissue repair, anti-inflammatoryPreclinical + small human studiesInjection (SC, IM, intra-articular)Addresses root cause of musculoskeletal pain
SemaglutideTRPV1 inhibition, anti-inflammatoryPreclinical + clinical (STEP-9)Injection (SC), oralFDA-approved drug with emerging pain data
GHK-CuNF-kB suppression, tissue regenerationIn vitro + animal studiesTopical, injectionNatural peptide with broad gene modulation
KPVNF-kB inhibitionPreclinicalInjection, oral, topicalPotent inflammation control in 3 amino acids
CJC-1295 + IpamorelinGH/IGF-1 tissue repairHuman PK studiesInjection (SC)Sustained GH elevation for recovery
TB-500Systemic tissue repair, angiogenesisPreclinical + cardiac trialsInjection (SC, IM)Broad systemic healing capacity
SS-31Mitochondrial protectionPreclinical + human trialsInjection (SC, IV)Targets pain at the mitochondrial level

Peptides vs. Conventional Pain Treatments

FactorNSAIDsOpioidsPeptides
Pain signal blockingYes (COX inhibition)Yes (mu receptor)Some (TRPV1, NF-kB)
Tissue repairNoNoYes (BPC-157, TB-500, GHK-Cu)
Addiction riskNoneHighNone documented
GI side effectsSignificantModerateMinimal
Inflammation reductionYes (non-selective)NoYes (pathway-specific)
Nerve repairNoNoSome (BPC-157, GHK-Cu)
FDA approval for painYesYesNo (except semaglutide for adjacent indications)
Long-term safety dataExtensiveExtensiveLimited

Combination Approaches: Peptide Stacking for Pain

Clinicians working with peptides increasingly use combinations that target multiple aspects of chronic pain simultaneously. While formal clinical trial data on combinations is scarce, the rationale is grounded in complementary mechanisms.

A common clinical protocol pairs BPC-157 with TB-500 -- BPC-157 for localized tissue repair and TB-500 for systemic healing support. Adding GHK-Cu brings antioxidant defense and collagen regeneration into the mix [22].

For neuropathic pain, a protocol might combine a tissue-repair peptide with a growth hormone secretagogue like CJC-1295 and Ipamorelin to boost IGF-1-driven nerve repair, plus SS-31 to protect mitochondrial function in damaged neurons.

For more on combining peptides safely, see the Peptide Stacking Guide.

An important caveat: Stacking peptides without medical supervision is risky. Interactions between multiple bioactive compounds are poorly understood, and individual responses vary widely. Always work with a qualified healthcare provider.

What the Evidence Supports (and Where It Falls Short)

The honest assessment of peptides for chronic pain is that the science is promising but incomplete.

What is well-supported:

  • BPC-157 accelerates tissue healing across dozens of preclinical models and has small human studies showing knee pain improvement
  • GLP-1 peptides like semaglutide directly inhibit TRPV1 pain receptors in lab and animal studies, with clinical trial data showing pain improvement in osteoarthritis
  • Growth hormone secretagogues reliably increase GH and IGF-1, which are established drivers of tissue repair

What needs more evidence:

  • Large, randomized, placebo-controlled trials for any peptide specifically indicated for chronic pain
  • Long-term safety data for most compounds
  • Head-to-head comparisons between peptides and established analgesics
  • Optimal dosing, duration, and combination protocols

What you should know:

Most pain-relevant peptides are not FDA-approved for pain treatment. BPC-157 and TB-500 are available through compounding pharmacies but are not commercially manufactured pharmaceuticals. Semaglutide is FDA-approved for diabetes and obesity but not for pain. The regulatory situation is shifting -- the FDA has restricted some peptides from compounding, and availability may change.

Frequently Asked Questions

Are peptides a replacement for pain medications?

Not at this stage. Peptides are better understood as complementary tools that address aspects of chronic pain that conventional medications do not touch -- particularly tissue repair and targeted inflammation reduction. Anyone managing chronic pain should work with their physician before adding or substituting treatments.

Which peptide has the most human evidence for pain?

Semaglutide, by far. It has large clinical trials (the STEP program) showing pain improvement in osteoarthritis, and it is FDA-approved for adjacent conditions. BPC-157 has the most human evidence among the non-approved peptides, though the studies are small and retrospective.

How long do peptides take to work for pain?

This varies significantly by compound and condition. BPC-157 has shown effects within weeks in human knee pain studies. Growth hormone secretagogues like CJC-1295 take time to elevate tissue repair capacity -- typically 4-8 weeks for noticeable recovery benefits. GLP-1 agonists can show pain improvements within weeks as inflammation decreases.

Are peptides safe for long-term use?

Long-term safety data is limited for most pain-related peptides. BPC-157 showed no adverse effects in a one-year rat study and in small human trials, but rigorous long-term human data does not exist. Semaglutide has the most extensive long-term safety data through its diabetes and obesity programs. Discuss duration of use with a healthcare provider.

Can peptides help with neuropathic pain specifically?

Several peptides show relevance. GLP-1 agonists reduce neuroinflammation in the spinal cord. BPC-157 promotes nerve regeneration after peripheral nerve injury. GHK-Cu stimulates BDNF production and nerve outgrowth. SS-31 protects neuronal mitochondria from oxidative damage. See our guide on best peptides for nerve regeneration for more detail.

The Bottom Line

Chronic pain affects over 50 million Americans and existing treatments leave major gaps. Peptides will not replace proven analgesics anytime soon, but they address dimensions of chronic pain that NSAIDs and opioids simply cannot -- tissue repair, nerve regeneration, targeted inflammatory pathway modulation, and mitochondrial protection.

BPC-157 has the broadest preclinical support for musculoskeletal pain. Semaglutide's TRPV1 inhibition represents a genuinely new mechanism that could reshape how we think about GLP-1 drugs. Growth hormone secretagogues support the body's own repair capacity. And mitochondria-targeted peptides like SS-31 go after the oxidative stress that sustains pain sensitization.

The field needs larger human trials, better safety data, and clearer regulatory pathways. But the molecular logic is sound, the preclinical results are consistent, and the clinical signals are encouraging. If you are dealing with chronic pain and interested in peptides, the conversation to have is with a physician who understands both your pain condition and the current state of peptide research.

References

  1. CDC. Facts About TBI. Traumatic Brain Injury & Concussion Data. https://www.cdc.gov/traumatic-brain-injury/data-research/facts-stats/index.html; NCHS National Health Statistics Reports No. 162. https://www.cdc.gov/nchs/data/nhsr/nhsr162-508.pdf

  2. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. American Journal of Sports Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/

  3. Referenced in Vasireddi et al. systematic review (Ref 2), reporting 7/12 patients with chronic knee pain experienced >6 months relief from single BPC-157 injection.

  4. Keremi B, et al. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Integrative Medicine. 2021. PMID: 34324435. https://pubmed.ncbi.nlm.nih.gov/34324435/

  5. Park J, et al. The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. Journal of Dental Anesthesia and Pain Medicine. 2022. PMC8995671. https://pmc.ncbi.nlm.nih.gov/articles/PMC8995671/

  6. Sikiric P, et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. Journal of Physiology (Paris). 1997. PMID: 9403784. https://pubmed.ncbi.nlm.nih.gov/9403784/

  7. Go EJ, Hwang SM, Jo H, et al. GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation. Experimental & Molecular Medicine. 2024;56:2570-2584. https://www.nature.com/articles/s12276-024-01342-8

  8. Referenced in He et al. (Ref 9) and GLP-1 clinical evidence summaries. STEP-9 trial: semaglutide in patients with obesity and knee osteoarthritis.

  9. He Y, et al. Advances in GLP-1 receptor agonists for pain treatment and their future potential. The Journal of Headache and Pain. 2025;26:45. https://link.springer.com/article/10.1186/s10194-025-01979-4

  10. Lee JH, et al. Semaglutide ameliorates diabetic neuropathic pain by inhibiting neuroinflammation in the spinal cord. Cells. 2024. Referenced in He et al. (Ref 9).

  11. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. PMC6073405. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/

  12. Referenced in Pickart & Margolina gene data review (Ref 11). GHK-Cu reduction of TNF-alpha-induced IL-6 in fibroblasts.

  13. Canapp SO Jr, et al. The Effect of Topical Tripeptide-Copper Complex on Healing of Ischemic Open Wounds. Veterinary Surgery. 2003;32(6):515-23.

  14. Bobyntsev II, et al. Effect of Gly-His-Lys peptide and its analogs on pain sensitivity in mice. Eksperimental'naia i Klinicheskaia Farmakologiia. 2015; Effects of tripeptide Gly-His-Lys in pain-induced aggressive-defensive behavior in rats. Bulletin of Experimental Biology and Medicine. 2017.

  15. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-31.

  16. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/

  17. CJC-1295 and Ipamorelin combination therapy pharmacology and clinical observations. Referenced in clinical practice summaries.

  18. Pilot study on GH circulation and quadriceps strength preservation post-ACL reconstruction. 2020. Referenced in clinical review data.

  19. Thymosin beta 4 and tissue repair. Multiple studies reviewed in Goldstein AL, et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012.

  20. Zhao W, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Journal of Neuroinflammation. 2019;16:230. PMC6865061. https://pmc.ncbi.nlm.nih.gov/articles/PMC6865061/

  21. Szeto HH. Stealth Peptides Target Cellular Powerhouses to Fight Rare Disease. Trends in Molecular Medicine. 2024. Referenced in SS-31 clinical trial summaries.

  22. Combination peptide therapy protocols. Referenced in clinical practice reviews, including Optimantra Peptide Therapy Trends 2026. https://www.optimantra.com/blog/peptide-therapy-trends-to-watch-in-2025-what-clinics-need-to-know